Lopinavir/ritonavir/rocuronium bromide interactionMyopathy following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1843卷 / 1期

关键词：

D O I：

10.1007/s40278-021-91333-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：231 / 231

相关论文

共 50 条

[31] DexamfetamineHypertension following off-label use: case report
Reactions Weekly, 2021, 1883 (1) : 150 - 150
[32] RituximabPancytopenia following off-label use: case report
Reactions Weekly, 2020, 1807 (1) : 176 - 176
[33] TocilizumabAnaphylaxis following off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 397 - 397
[34] RisdiplamPneumonia following off-label use: case report
Reactions Weekly, 2023, 1950 (1) : 348 - 348
[35] RivoceranibNeurotoxicity following an off-label use: case report
Reactions Weekly, 2018, 1702 (1) : 232 - 232
[36] MethotrexateSteatohepatitis following off-label use: case report
Reactions Weekly, 2019, 1768 (1) : 225 - 225
[37] AzacitidineDiarrhoea following off-label use: case report
Reactions Weekly, 2019, 1736 (1) : 48 - 48
[38] TocilizumabNeutropenia following off-label use: case report
Reactions Weekly, 2021, 1853 (1) : 446 - 446
[39] SunitinibCardiomyopathy following off-label use: case report
Reactions Weekly, 2023, 1971 (1) : 240 - 240
[40] PrednisoloneInefficacy following off-label use: case report
Reactions Weekly, 2022, 1910 (1) : 405 - 405

← 1 2 3 4 5 →